Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6349776 | 0.90 | MEN1 (0.63) | PKMHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2069934 | 0.88 | PKM (1.00) | PKMHTTGAAATMALDH1A1 | |
| SCHEMBL1954190 | 0.84 | CXCR1 (0.54) | PKMHTTGAAATMALDH1A1 | |
| SCHEMBL15160073 | 0.84 | HTT (0.53) | PKMHTTGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL28573397 | 0.84 | NPC1 (0.60) | PKMHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL16603070 | 0.84 | PKM (0.72) | PKMHTTGAAALDH1A1GLA | |
| SCHEMBL6162009 | 0.83 | PKM (0.53) | PKMHTTGAAATMALDH1A1 | |
| SCHEMBL2831541 | 0.83 | MAPT (0.53) | PKMHTTGAAALDH1A1GLA | |
| SCHEMBL3010106 | 0.83 | HTT (0.52) | PKMHTTGAAATMALDH1A1 | |
| SCHEMBL29053787 | 0.83 | GAA (0.56) | PKMHTTGAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884063-B2 | Amido-substituted azole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9884063-B2 | Amido-substituted azole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20170020886-A1 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150449-A2 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | PKM 2287/4885HTT 846/4885GAA 569/4885 |
| US-20170020886-A1 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | TNK1, TNNI3K, TNKS | PKM 646/4885HTT 3197/4885GAA 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.